Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time

Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time


In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. 

Justin Sullivan | Getty Images

A federal bankruptcy judge on Friday rejected Johnson & Johnson‘s second attempt to resolve tens of thousands of lawsuits alleging the company’s talc baby powder and other talc-based products caused cancer. 

J&J in 2021 offloaded those talc liabilities into a new subsidiary, LTL Management, and immediately filed for Chapter 11 bankruptcy protections. 

Judge Michael Kaplan in Trenton, New Jersey, said in an opinion that LTL Management’s second bankruptcy must be dismissed because the subsidiary was not in “imminent” or “immediate financial distress.” A U.S. appeals court in April dismissed the first bankruptcy attempt over the same reason. 

The decision jeopardizes J&J’s proposed $8.9 billion settlement that would stop new lawsuits from being filed. The company previously said more than 60,000 claimants have already committed to voting in favor of the plan.

“LTL commenced its bankruptcy case in good faith and in strict compliance with the Bankruptcy Code,” J&J said in a statement. 

“The Bankruptcy Code does not require a business to be engulfed in ‘flames’ to seek a reorganization supported by the vast majority of claimants,” said Erik Haas, J&J’s worldwide vice president of litigation in the statement.

J&J contends that research and clinical evidence demonstrates that its talc products remain safe.



Source

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
Health

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”  “They’re going to be tariffs […]

Read More